Id3 upregulates BrdU incorporation associated with a DNA damage response, not replication, in human pancreatic beta-cells.

Publication Year: 
Seung-Hee Lee , Ergeng Hao , Fred Levine , Pamela Itkin-Ansari
Public Summary: 
Scientific Abstract: 
Elucidating mechanisms of cell cycle control in normally quiescent human pancreatic beta-cells has the potential to impact regeneration strategies for diabetes. Previously we demonstrated that Id3, a repressor of basic Helix-Loop-Helix (bHLH) proteins, was sufficient to induce cell cycle entry in pancreatic duct cells, which are closely related to beta-cells developmentally. We hypothesized that Id3 might similarly induce cell cycle entry in primary human beta-cells. To test this directly, adult human beta-cells were transduced with adenovirus expressing Id3. Consistent with a replicative response, beta-cells exhibited BrdU incorporation. Further, Id3 potently repressed expression of the cyclin dependent kinase inhibitor p57 (Kip2 ) , a gene which is also silenced in a rare beta-cell hyperproliferative disorder in infants. Surprisingly however, BrdU positive beta-cells did not express the proliferation markers Ki67 and pHH3. Instead, BrdU uptake reflected a DNA damage response, as manifested by hydroxyurea incorporation, gH2AX expression, and 53BP1 subcellular relocalization. The uncoupling of BrdU uptake from replication raises a cautionary note about interpreting studies relying solely upon BrdU incorporation as evidence of beta-cell proliferation. The data also establish that loss of p57 (Kip2) is not sufficient to induce cell cycle entry in adult beta-cells. Moreover, the differential responses to Id3 between duct and beta-cells reveal that beta-cells possess intrinsic resistance to cell cycle entry not common to all quiescent epithelial cells in the adult human pancreas. The data provide a much needed comparative model for investigating the molecular basis for this resistance in order to develop a strategy for improving replication competence in beta-cells.

© 2013 California Institute for Regenerative Medicine